Established in 1950, Taro Pharmaceutical Industries Ltd is a research-based international specialty pharmaceutical company that develops, manufactures, and markets prescription brand and generic and OTC pharmaceutical products. Taro’s research programs and niche product development strategy have allowed the company to achieve a strong leadership position in the US dermatology market.

Taro is uniquely positioned to be a consistent strong player based on its niche product portfolio and differentiated development capabilities, supported by state-of-the-art manufacturing facilities in Canada and Israel. Additionally, Taro’s advanced capabilities across the value chain, from active pharmaceutical ingredient development to its customer-facing sales force and distribution, allow it to control the quality and costs augmented by an efficient supply chain infrastructure, maximizing the returns and eliminating risks due to dependencies on external factors. These collective strengths have resulted in Taro’s achieving a strong commercial position among customers, highlighted by a market-leading customer service level rating.

Taro has demonstrated enviable growth over the past 5 years, translating into record levels of net sales with zero debt. The focus on cost control and efficiency, along with strong backing by Sun Pharmaceutical Industries Ltd, a major shareholder of Taro’s, has resulted in a significant cash position to provide a platform for growth. Sun Pharma is the world’s fifth-largest generic specialty pharmaceutical company, with a presence in more than 50 countries.

Taro’s US customer mix is well diversified among retail chains, drug wholesalers, managed care providers, government entities, and other classes of trade, resulting in a well-balanced market presence. Taro’s products rank No. 1 in market share for about 40% of its portfolio.

To learn more about Taro’s high-quality, affordable products, visit Whether you are a patient, a pharmacist, or a physician, Taro is there.
For more information, visit